Form 8-K - Current report:
SEC Accession No. 0001193125-24-168501
Filing Date
2024-06-26
Accepted
2024-06-26 06:40:01
Documents
15
Period of Report
2024-06-26
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d860197d8k.htm   iXBRL 8-K 60589
2 EX-99.1 d860197dex991.htm EX-99.1 45440
6 GRAPHIC g860197page6.jpg GRAPHIC 6333
  Complete submission text file 0001193125-24-168501.txt   249048

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA svra-20240626.xsd EX-101.SCH 2866
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE svra-20240626_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE svra-20240626_pre.xml EX-101.PRE 10823
19 EXTRACTED XBRL INSTANCE DOCUMENT d860197d8k_htm.xml XML 3515
Mailing Address 6836 BEE CAVE ROAD BUILDING 3, SUITE 201 AUSTIN TX 78746
Business Address 6836 BEE CAVE ROAD BUILDING 3, SUITE 201 AUSTIN TX 78746 51285113796
Savara Inc (Filer) CIK: 0001160308 (see all company filings)

EIN.: 841318182 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32157 | Film No.: 241070584
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)